Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Hamakawa Y, Agemi Y, Shiba A, Ikeda T, Higashi Y, Aga M, Miyazaki K, Taniguchi Y, Misumi Y, Nakamura Y, Shimokawa T, Saigusa Y, Kobayashi N, Okamoto H, Kaneko T.
Hamakawa Y, et al. Among authors: aga m.
Cancer Med. 2023 Sep;12(17):17788-17797. doi: 10.1002/cam4.6405. Epub 2023 Aug 7.
Cancer Med. 2023.
PMID: 37548381
Free PMC article.